Stay updated on Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial
Sign up to get notified when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.

Latest updates to the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page
- ChecktodayChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check37 days agoChange DetectedThe webpage has undergone significant updates, including the introduction of a new study on RGX-314 for treating neovascular age-related macular degeneration (nAMD) and the removal of detailed information about previous anti-VEGF therapies. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference28%
- Check44 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check87 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check102 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
Stay in the know with updates to Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.